
New antibiotic is effective against gonorrhea, could be first new treatment since 1990s, study says
A new type of antibiotic for treatment of urinary tract infections in women could also work against gonorrhea infections, a new study finds. This could put the medication, called gepotidacin, on track to become the first new antibiotic for gonorrhea since the 1990s.
'Gepotidacin is a novel oral antibacterial treatment with the potential to become an alternative option for the treatment of gonococcal infections, supported by an acceptable safety and tolerability profile,' the researchers wrote in the study published Monday in The Lancet, adding that the drug 'could mark a meaningful advancement in patient care.'
As an antibiotic, gepotidacin works by inhibiting bacteria from replicating in the body. In March, it was approved by the US Food and Drug Administration to treat uncomplicated urinary tract infections in women and girls ages 12 and older. Recurrent UTIs have become a bigger problem as the bacteria that cause them have become more resistant to the antibiotics available to treat them.
Now, there is new hope that gepotidacin may help fight drug-resistant gonorrhea.
'The big takeaway is that having additional treatment options for gonorrhea is fantastic,' said Dr. Jason Zucker, an infectious disease and sexually transmitted infections expert and assistant professor of medicine at Columbia University Vagelos College of Physicians and Surgeons, who was not involved in the new study.
Effective treatments for gonorrhea have become increasingly limited in recent years due to the global rise of antimicrobial resistance in Neisseria gonorrhoeae, the bacteria that cause gonorrhea, rendering many previously used first-line antibiotics ineffective.
The current standard of care involves an intramuscular injection of the antibiotic ceftriaxone, which requires a visit to a care facility.
A key benefit of gepotidacin is that it would not involve an injection at the doctor's office, which could make treating gonorrhea more convenient for patients, Zucker said.
'Right now, patients come in, especially if they are not having symptoms, if they test positive, we have to ask them to come back. For some people, that's not so easy,' he said. 'So obviously, the ability to have the pharmacy send treatment to their house, or have them be able to pick it up, would really make things a lot easier for people and reduce the number of doctor visits they have, especially if they have jobs where they don't have a lot of time off.'
Gonorrhea can lead to serious health problems if left untreated, and though rare, can even spread to the blood or joints. Among women, untreated gonorrhea can cause an infection of the reproductive organs called pelvic inflammatory disease, which can lead to a greater risk of pregnancy complications and infertility. In men, gonorrhea also can lead to infertility in rare cases.
In the United States, gonorrhea and other sexually transmitted infections or STIs have become more common. Reported cases of three nationally notifiable STIs – chlamydia, gonorrhea and syphilis – were up 90% in the US in 2023 compared with about two decades prior in 2004, according to data released last year by the US Centers for Disease Control and Prevention. More than 2.4 million cases of STIs were reported in 2023 nationally.
The Phase 3 trial, conducted between October 2019 and October 2023, included more than 600 people ages 12 and older who were diagnosed with gonorrhea in the urogenital area across six countries: Australia, Germany, Mexico, Spain, the United Kingdom and the United States.
The study was funded by the pharmaceutical company GSK, which developed the antibiotic, and the development of gepotidacin was funded in part with federal funds from the US Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, and the Defense Threat Reduction Agency, according to GSK.
About half of the study participants were treated with a gepotidacin regimen of two oral doses administered about 10 to 12 hours apart, at 3,000-milligrams per dose. The other participants were provided with the current standard treatment of administering a single dose of the antibiotic ceftriaxone as an injection paired with orally taking the antibiotic azithromycin.
The trial data, which is being presented at the European Society of Clinical Microbiology and Infectious Diseases conference, showed that gepotidacin was as effective as the current leading combination treatment, and was also effective against treatment-resistant infections, which occur when strains of gonorrhea are resistant to currently used antibiotics.
The gonorrhea infections were cured among 92.6% of the study participants who were administered gepotidacin compared with 91.2% of the study participants who were treated with ceftriaxone plus azithromycin.
Among the 7.4% of participants in the gepotidacin group who were not successfully treated, they all were due to missing data, according to GSK, which added that 'in participants with complete data, there was no bacterial persistence at the urogenital body site.'
While the study primarily assessed gepotidacin as a treatment for urogenital gonorrhea, some participants with rectal and throat infections were evaluated. Of those with complete data, the study showed that it was more difficult to treat gonorrhea in the throat compared with other body sites, as 14 out of 16 people with throat gonorrhea and complete data – 88% – were successfully treated.
The researchers wrote that the prevalence of throat infections 'warrants further investigation' in a larger group of participants, as does studying the efficacy of geptodiacin in the treatment of gonorrhea in the throat.
'Pharyngeal gonorrhea is notoriously harder to treat and plays a key role in silent transmission and resistance development, so having reliable oral options at all anatomical sites is critical,' Zucker, said.
The international team of researchers found no life-threatening nor fatal side effects associated with either treatment approach used in the study, but the gepotidacin group had higher rates of side effects compared with the ceftriaxone-plus-azithromycin group, which were mostly gastrointestinal, such as diarrhea and nausea, and almost all were mild or moderate, according to the study.
'One of the challenges is that a lot of oral antibiotics have GI side effects,' Zucker said.
The researchers noted that it will be important to investigate the efficacy of gepotidacin for treating gonorrhea in groups not primarily represented in the study especially women and Black and Brown communities, as 92% of participants in the study were men, 74% were White and 71% were men who have sex with men.
If gepotidacin is approved for the treatment of gonorrhea in the United States, 'the price will be disclosed when the product will be supplied in a market. Our approach would be for it to reflect the value and outcomes they bring to patients, providers and payers while being sensitive to market and societal expectations,' according to a GSK spokesperson.
Bluejepa, the brand name for the version of gepotidacin approved in the United States to treat UTIs, is expected to be available in the second half of 2025.
The new study was 'very well-done' with 'rigorous data,' and having more options to treat gonorrhea is critical for slowing down the bacteria's drug resistance, said Dr. Jeffrey Klausner, a clinical professor of public health at the University of Southern California's Keck School of Medicine in Los Angeles, who was not involved in the trial.
'The more options doctors have to treat gonorrhea means that they do not have to use the same drug over and over again, which is a recipe for disaster and more resistance. We know that using the same drug over and over again leads to drug resistance,' Klausner said in the email. 'If gepotidacin is approved and recommended for gonorrhea treatment, that is a true advance and will greatly help our efforts to slow down drug resistance in gonorrhea.'
In the study, researchers noted that using gepotidacin to treat gonorrhea as an oral treatment option, not an injection, may be more efficient and reduces the risk of persistent, drug-resistant infections.
Yet there is some concern that strains of gonorrhea may eventually develop resistance to gepotidacin, according to a comment paper accompanying the new study in The Lancet.
'In our opinion, N gonorrhoeae will also develop gepotidacin resistance when the selective pressure increases and where compliance to the dual-dose regimen is suboptimal,' Magnus Unemo of Örebro University in Sweden and Teodora Wi of the World Health Organization in Switzerland wrote in the paper.
'Due to the inherent ability of gonococci to develop resistance, difficulties in increasing the gepotidacin dose due to adverse events, and the lack of other treatment options, preclinical and clinical development of additional gonorrhoea treatments remains important,' they wrote. 'In conclusion, gepotidacin is promising for the treatment of gonorrhoea, but the challenges to retain gonorrhoea as a treatable infection will continue.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
10 hours ago
- Medscape
HHS Journal Ban Won't Stop Corruption — It'll Make It Worse
Robert F. Kennedy Jr has threatened to bar federal scientists from publishing in top medical journals. This move risks backfiring on two major fronts. First, it will only accelerate private industry's sway over the scientific record. Second, launching new, government-run journals will demand vast resources and years of effort — and still won't earn the credibility of established publications. With nearly five decades in medical and scientific writing, editing, and publishing — across nonprofit and commercial organizations, legacy print and digital platforms, and both subscription-based and open-access models — I write from experience. To see the flaws in Kennedy's proposal, we need to understand what works and what doesn't in science publishing. Primary, peer-reviewed medical/scientific literature has evolved and thrived in a culture of self-criticism, through letters columns, corrections, retractions, and open debate. The New England Journal of Medicine (NEJM) , The Lancet , and JAMA remain the gold standards in medical publishing because of their rigorous peer review, global reach, and editorial independence from government or corporate influence. Here's where RFK Jr's main objection with the current system seems to lie. The Secretary has portrayed medical journals as hopelessly corrupted by industry. Extensive firewalls, guidelines, and rules have been established to govern the relationship of industry to medical journals. They rest largely on honest disclosure with authors, editors, and readers paying attention. Cracks in those barriers are not unknown. But the solution lies in strengthening these firewalls, not sidelining them. A ban on government employees from submitting to NEJM , The Lancet , JAMA, and other top-tier titles will deliver more power — not less — to pharmaceutical, device, and biotech companies to set the scientific agenda. Far from reducing 'corruption,' such a misguided policy would magnify the role of the very stakeholders RFK Jr decries. And if federal grant support diminishes, the research that is published will become increasingly supported by industry, compounding the mistake. The notion of creating new government-owned medical journals from scratch is not an absurd idea. But Kennedy's illusion of fast-tracking NIH-affiliated "preeminent journals" that stamp federal‐funded work as unquestionably legitimate is a gargantuan endeavor. Building editorial boards, peer‐review standards, submission platforms, indexation in PubMed, and marketing to researchers worldwide takes years of work from countless individuals and would cost a substantial amount of money. Even then, a journal's reputation rests on trust and perceived independence. Readers judge not only the science but also the integrity of the editor–owner relationship. The hazard is that the owner (the government) would have to be trusted by the readers, or no one would bother reading these publications. A government 'house organ' would likely be viewed skeptically if the federal government can withdraw or prohibit publications at will. Banning federal scientists from submitting to journals the administration doesn't like does not cleanse the literature of industry influence — it deepens those ties. And while government-run journals might one day exist, they won't arrive fully baked, credible, or conflict-free. Better to invest in the proven mechanisms of editorial independence, enhanced peer review, and clearer disclosure than in a rushed, state-controlled alternative destined to struggle for trust and impact. If RFK Jr wants a better list of reforms, here's what I suggest: Take on predatory publishers and their fake journals, fake authors, and fabricated institutions and references — a threat that existed even before generative chat powered by artificial intelligence (AI). Take aim at rapacious mainstream publishers, whose excess profit margins and subscription price gouging represent a financial drain on researchers, readers, and academic libraries. Crack down on excessively large author fees to have an article considered/reviewed/published. Promote the publication of reproducibility studies. Raise the alarm about the use of AI in peer view and the creation of manuscripts — including the data in them. These steps aren't as sexy as proclaiming publishing bans for government scientist or launching new journals on whose mastheads you can put your own name. But they have the virtues of solving real problems and not making existing problems worse — which, as a physician, seems like something I've heard before somewhere …
Yahoo
a day ago
- Yahoo
New test could transform diagnosis and treatment of STIs
A new rapid test for sexually transmitted infections could soon transform on-the-spot diagnosis and treatment. Birmingham-based Linear Diagnostics has secured £1 million in funding to develop the technology, which could deliver results in less than 20 minutes. The funding comes from the NIHR Invention for Innovation programme and will support a three-year project to finalise the test and prepare it for clinical trials. Dr Jean-Louis Duprey, head of research and development at Linear Diagnostics, said: "We are developing a near patient device that will overcome this conundrum." The company is working with the NIHR HealthTech Research Centre and the North East Innovation Lab to deliver the project. Dr Jana Suklan, senior methodologist at the HRC, said: "The NIHR HRC in Diagnostic and Technology Evaluation is delighted to be collaborating with the North East Innovation Lab to support Linear Diagnostics with their exciting technology. "Our research involves analysing unmet needs, examining current practice and identifying the most promising point in the patient pathway for implementing the technology." The test uses Linear's Exponential Amplification (EXPAR) technology, which detects bacterial DNA within minutes. The company has focused on STIs such as Neisseria gonorrhoeae and Chlamydia trachomatis, where rapid diagnosis is essential to prevent further transmission and begin treatment immediately.


New York Post
2 days ago
- New York Post
Simple tool could detect Parkinson's disease early — it was 96% accurate in experiments
This pen truly is mightier than the sword. A team of researchers at UCLA has developed a high-tech diagnostic pen that can detect signs of Parkinson's disease with over 96% accuracy, offering a low-cost way to identify the neurodegenerative disorder far earlier than now. A pilot study in the journal Nature Chemical Engineering unveiled the device, which looks much like a regular pen. 3 A patient with PD using the diagnostic pen for a writing task. Nature Chemical Engineering It's able pick up on subtle motor dysfunctions before they're visible to the naked eye, all by analyzing how people write. So, how does this futuristic fountain pen work? The tip is made of a flexible silicone material infused with magnetic particles, and it writes using a special ferrofluid ink that contains nanomagnets. As someone writes, pressure from the hand deforms the tip, causing changes in magnetic fields that produce electrical signals — like a Morse code of motor function. Those signals are then analyzed to detect the difference between healthy and Parkinson's-affected motor patterns. In tests with 16 participants — including 3 with Parkinson's — the system nailed the diagnosis with 96.22% accuracy. Even more impressive? The pen worked whether people wrote on paper or in the air, meaning it doesn't even require a surface. 3 Nature Chemical Engineering Today, Parkinson's is largely diagnosed based on observations, which are subjective, or by biomarker-based imaging, which can be expensive. This diagnostic pen is portable, inexpensive and doesn't rely on a neurologist to interpret results, making it a promising option for remote screenings, home use or even telehealth checkups. 'Our development of the diagnostic pen represents a low-cost, widely disseminable and reliable technology with the potential to improve PD diagnostics across large populations and resource-limited areas,' the researchers wrote. With further validation in a larger population, the device could be used not just for early diagnosis, but for ongoing symptom tracking and personalized treatment monitoring. 3 Today, Parkinson's is largely diagnosed based on observations, which are subjective, or by biomarker-based imaging, which can be expensive. highwaystarz – This is just the latest innovation aimed at tackling Parkinson's disease, which affects more than 10 million people worldwide and has no known cure. A recent study found that psilocybin — the psychedelic compound that gave 'magic mushrooms' their trippy reputation in the 1960s — showed serious promise for improving mood and motor function in people with Parkinson's disease. Tavapadon — a new drug that mimics dopamine by targeting certain receptors — has also shown promise in clinical trials by reducing motor fluctuations and maintaining symptom control with fewer side effects than traditional therapies. Produodopa — a continuous infusion therapy first administered in the UK — was approved by the US Food and Drug Administration last fall. Innovative approaches targeting the psychological aspects of the disease have been successful as well — with tandem cycling proving to be especially popular. Some New Yorkers even find relief by playing pingpong.